RET-IN-31

CAT: 0804-HY-178786Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-178786Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
RET-IN-31 (Compound 13) is an orally active, selective RET inhibitor (IC50s: 1.4 nM, 1.9 nM, 3.8 nM for RETWT, RETV804L, RETV804M, respectively) . RET-IN-31 inhibits hERG and Cytochrome P450 (IC50s: 13.6 μM, 7.9 μM, 12.8 μM, 16.9 μM, 8.9 μM, 13.0 μM for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4-M, CYP3A4-T, respectively) . RET-IN-31 has anti-cancer effects against activated RET mutations and gene fusion-driven cancers[1].
CAS Number
[2491726-04-4]
UNSPSC
12352005
Target
Cytochrome P450; Potassium Channel; RET
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CC1=CC(NC2=CC(C)=NC(N3CC4N(C(C5=CN=C(N6N=CC(F)=C6)C=C5)=O)C(CC4)C3)=N2)=NN1
Molecular Formula
C24H25FN10O
Molecular Weight
488.52
References & Citations
[1]Mohammed S, et al. Discovery of 2- (4-Ureido-piperidin-1-yl) -4-morpholinothieno [3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-Kinase Inhibitors with In Vitro and In Vivo Antitumor Efficacy in Triple-Negative Breast Cancer. J Med Chem. 2025 Oct 23;68 (20) :21282-21317.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP1; CYP2; CYP3

Related Products

CatalogName
HY-133553-01RET-IN-3
HY-153676-01RET-IN-23
HY-148742-01RET-IN-21
HY-145024RET-IN-6
HY-145023RET-IN-5
HY-147563RET-IN-17
HY-144422RET-IN-15
HY-112950RET-IN-1
HY-168105RET-IN-27
HY-151987RET-IN-20

Alternative Products

CatalogName
R1701-17RET protein (RET)
V8277-100UGRET Antibody / c-RET
V8276-100UGC-RET Antibody / RET
030597RET (Ret Proto-oncogene)
E8ET1611-98Ret

Popular Products